Shares of Rigel Pharmaceuticals (NASDAQ: RIGL) closed up 17% on Thursday as investors further digested the company's update on Wednesday.
The business update, as the company called it, had a bit of everything.
Rigel disclosed preliminary third-quarter sales of $11.7 million for Tavalisse, its treatment for a blood disorder called chronic immune thrombocytopenia (ITP). That sales number represented a 15% increase over the second quarter. Rigel estimates that the U.S. ITP market is about $1 billion, so it has plenty of potential for further growth.
On the pipeline front, Rigel noted that it completed a phase 1 study for R835, which inhibits a protein involved in the inflammatory response. The study was in healthy subjects but included a lipopolysaccharide challenge that induced an immune response -- measured with biomarkers -- in subjects given placebo, which was dampened in subjects given R835. Rigel is still contemplating which disease to test R835 in first.
Rigel also disclosed a new pipeline drug candidate, R552, which targets a protein involved in neurodegenerative and immune-mediated diseases. The company is testing R552 in a phase 1 study and is working on a follow-on candidate that will work in the central nervous system for neurodegenerative diseases.
The pipeline updates are nice, but the near-term value for Rigel is clearly tied to Tavalisse. A 15% quarter-over-quarter increase is substantial, but it's working off a low base. Rigel is pretty cheap for a biotech. With a market cap under $350 million, there isn't too much growth priced in.
In addition to growing sales in the U.S., Tavalisse is likely to gain approval in Europe after a positive preliminary vote by EU regulators. A final vote is expected next month, which could set up a rollout in Europe through its partner Grifols starting in 2020.
10 stocks we like better than Rigel Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Rigel Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of June 1, 2019
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
In This StoryRIGL
Latest Markets Videos
- Stimulus Update: MIllions Will Get a Stimulus Check in June. Are You One of Them?
- Social Security Checks Could Soar in 2023: Here's How Much Extra Seniors Might Receive
- Better Buy: Dogecoin vs. Terra Classic vs. Terra (LUNA)?
- Bitcoin Uses 50 Times Less Energy Than Traditional Banking, New Study Shows